CA
NBIX icon

Crewe Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Crewe Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2
Closed -$252 – 1029
2025
Q2 		$252 Hold
2
– – ﹤0.01% 717
2025
Q1 		$222 Hold
2
– – ﹤0.01% 691
2024
Q4 		$273 Buy
+2
New +$247 ﹤0.01% 620
2024
Q2 		– Sell
-700
Closed -$96.5K – 1006
2024
Q1 		$96.5K Buy
+700
New +$95.6K 0.01% 279
2023
Q2 		– Sell
-124
Closed -$12.6K – 970
2023
Q1 		$12.6K Hold
124
– – ﹤0.01% 504
2022
Q4 		$14.8K Hold
124
– – ﹤0.01% 473
2022
Q3 		$13K Hold
124
– – ﹤0.01% 585
2022
Q2 		$12K Buy
+124
New +$11.4K ﹤0.01% 554
2020
Q4 		– Sell
-6
Closed -$1K – 581
2020
Q3 		$1K Buy
+6
New +$694 ﹤0.01% 595

Other funds holding NBIX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return